Merck Life Sciences is a leader in biomarker immunoassays, including 197 MILLIPLEX® MAP multiplex kits with over 1,200 different analytes, for use with Luminex® instrumentation, an ultra-high sensitivity platform for Single Molecule Counting (SMC™), including instrumentation and assays, and a broad portfolio of ELISA kits, all with best-in-class validation. Merck offers the broadest available selection of unique analytes, as well as custom immunoassay development services, allowing you to pick your platform, degree of customization, and validation levels and types to meet investigational or translational research needs. Merck continues to update their portfolio in areas such as oncology and neuroscience. Merck’s latest application area combines high sensitivity anti-drug antibody (ADA) detection using SMC™ technology, combined with MILLIPLEX® MAP multiplex detection of immunoglobulin subtypes and complement pathways. For the first time you can detect ADA and subclass the immunoglobins and then study the effect on the complement pathway all in one portfolio. Look closer, all biomarker kits are not created equal - we set the performance criteria during assay development and uphold it for subsequent lots to ensure reproducible results you can trust.